These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 37108685)
1. A Protocol for Simultaneous In Vivo Imaging of Cardiac and Neuroinflammation in Dystrophin-Deficient MDX Mice Using [ Tang JM; McClennan A; Liu L; Hadway J; Ronald JA; Hicks JW; Hoffman L; Anazodo UC Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108685 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy. Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083 [TBL] [Abstract][Full Text] [Related]
3. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Wasala NB; Bostick B; Yue Y; Duan D Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935 [TBL] [Abstract][Full Text] [Related]
4. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy. Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493 [TBL] [Abstract][Full Text] [Related]
5. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy. Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884 [TBL] [Abstract][Full Text] [Related]
6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy. Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351 [TBL] [Abstract][Full Text] [Related]
7. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492 [TBL] [Abstract][Full Text] [Related]
8. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. van Putten M; Kumar D; Hulsker M; Hoogaars WM; Plomp JJ; van Opstal A; van Iterson M; Admiraal P; van Ommen GJ; 't Hoen PA; Aartsma-Rus A Neuromuscul Disord; 2012 May; 22(5):406-17. PubMed ID: 22284942 [TBL] [Abstract][Full Text] [Related]
9. Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases. Delfín DA; Zang KE; Schill KE; Patel NT; Janssen PM; Raman SV; Rafael-Fortney JA Neuromuscul Disord; 2012 Nov; 22(11):1006-14. PubMed ID: 22749475 [TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy. Gutpell KM; Hrinivich WT; Hoffman LM PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927 [TBL] [Abstract][Full Text] [Related]
15. Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. Ahmad N; Welch I; Grange R; Hadway J; Dhanvantari S; Hill D; Lee TY; Hoffman LM BMC Musculoskelet Disord; 2011 Jun; 12():127. PubMed ID: 21639930 [TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy. Oliveira-Santos A; Dagda M; Burkin DJ Hum Mol Genet; 2022 Jul; 31(14):2358-2369. PubMed ID: 35157045 [TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy. Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy. Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792 [TBL] [Abstract][Full Text] [Related]
19. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways. Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617 [TBL] [Abstract][Full Text] [Related]
20. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Rayavarapu S; Coley W; Cakir E; Jahnke V; Takeda S; Aoki Y; Grodish-Dressman H; Jaiswal JK; Hoffman EP; Brown KJ; Hathout Y; Nagaraju K Mol Cell Proteomics; 2013 May; 12(5):1061-73. PubMed ID: 23297347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]